How Royalty Pharma’s New AI and Dealmaking Hires Could Shape RPRX’s Royalty Sourcing Strategy

Simply Wall St.03-25

Royalty Pharma has recently strengthened its leadership bench, appointing former IQVIA technology leader Lucas Glass as Head of Artificial Intelligence and bringing in Greg Butz from Bank of America ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622502011?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-03-25 06:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622502011","market":"us","top_or_hot":-1,"title":"How Royalty Pharma’s New AI and Dealmaking Hires Could Shape RPRX’s Royalty Sourcing Strategy","media":"Simply Wall St.","content":"<div>\n<p>Royalty Pharma has recently strengthened its leadership bench, appointing former IQVIA technology leader Lucas Glass as Head of Artificial Intelligence and bringing in Greg Butz from Bank of America ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-royalty-pharmas-new-ai-and-dealmaking-hires-could-shape\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Royalty Pharma’s New AI and Dealmaking Hires Could Shape RPRX’s Royalty Sourcing Strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Royalty Pharma’s New AI and Dealmaking Hires Could Shape RPRX’s Royalty Sourcing Strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-25 06:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-royalty-pharmas-new-ai-and-dealmaking-hires-could-shape><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Royalty Pharma has recently strengthened its leadership bench, appointing former IQVIA technology leader Lucas Glass as Head of Artificial Intelligence and bringing in Greg Butz from Bank of America ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-royalty-pharmas-new-ai-and-dealmaking-hires-could-shape\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-royalty-pharmas-new-ai-and-dealmaking-hires-could-shape","article_id":"2622502011","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-royalty-pharmas-new-ai-and-dealmaking-hires-could-shape","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622502011","pubTimestamp":1774390429,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Royalty Pharma has recently strengthened its leadership bench, appointing former IQVIA technology leader Lucas Glass as Head of Artificial Intelligence and bringing in Greg Butz from Bank of America as Executive Vice President, Partnering & Investments, alongside elevating Chris Hite to Chairman, Partnering & Investments and expanding its regional leadership with a new Head of Asia.\nThese hires point to a company-wide push to embed artificial intelligence into decision-making and broaden...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","BK4587":"ChatGPT概念","RPRX":"Royalty Pharma plc","BK4528":"SaaS概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4023":"应用软件","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4543":"AI","AI":"C3.ai, Inc.","BK4007":"制药"},"translate_title":"Royalty Pharma的新人工智能和交易招聘如何塑造RPRX的特许权使用费采购策略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIYY":0.6,"RPRX":1.5,"AI":0.72},"content_text":"Royalty Pharma has recently strengthened its leadership bench, appointing former IQVIA technology leader Lucas Glass as Head of Artificial Intelligence and bringing in Greg Butz from Bank of America as Executive Vice President, Partnering & Investments, alongside elevating Chris Hite to Chairman, Partnering & Investments and expanding its regional leadership with a new Head of Asia. These hires point to a company-wide push to embed artificial intelligence into decision-making and broaden global deal sourcing, potentially reshaping how Royalty Pharma evaluates, originates, and structures royalty transactions across regions and therapeutic areas. We’ll now examine how the new Head of Artificial Intelligence role could influence Royalty Pharma’s investment narrative and future royalty sourcing. This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.AdvertisementRoyalty Pharma Investment Narrative RecapTo own Royalty Pharma, you need to believe its scale and data-driven approach can keep sourcing attractive biopharma royalties despite legal, pricing, and competition headwinds. The leadership additions around AI and global dealmaking may incrementally support near term deal quality, but they do not directly change the most pressing risks around the Vertex Alyftrek royalty dispute and intensifying competition for attractive assets. The appointment of Lucas Glass as Head of Artificial Intelligence is especially relevant here, because it sits at the intersection of risk management and sourcing new royalties. If AI tools improve screening, pricing, and monitoring of deals, that could matter for how Royalty Pharma contends with more aggressive competitors and complex policy and IP environments tied to its key growth catalysts. But while the leadership story sounds positive, investors should also be aware that... Read the full narrative on Royalty Pharma (it's free!)Royalty Pharma's narrative projects $4.0 billion in revenue and $922.7 million in earnings by 2028. This requires 20.0% yearly revenue growth and an earnings decrease of about $77 million from $1.0 billion today.Uncover how Royalty Pharma's forecasts yield a $51.56 fair value, a 13% upside to its current price.Exploring Other PerspectivesRPRX 1-Year Stock Price Chart Lower end analysts were already cautious, assuming around US$3.5 billion of revenue and US$893.9 million of earnings by 2028, and seeing drug pricing and IP erosion as bigger threats than consensus. With the new AI and deal sourcing hires, you now have to weigh whether those more pessimistic views on regulation and competition still hold, or if they may soften as the story evolves.Explore 5 other fair value estimates on Royalty Pharma - why the stock might be worth 10% less than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Royalty Pharma research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free Royalty Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Royalty Pharma's overall financial health at a glance.Interested In Other Possibilities?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.Uncover the next big thing with 30 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622502011","isCrawlerRequest":true}